CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) was upgraded by StockNews.com to a “sell” rating in a report released on ...

Shares of CRISPR Therapeutics CRSP closed at $40.97 on Tuesday, close to their 52-week low of $36.52. This decline in CRSP ...

CRISPR Therapeutics CRSP stock rose more than 25% in the past week, thanks to the encouraging fourth-quarter 2024 results and a rating upgrade by a Wall Street analyst. Though CRSP’s quarterly ...

Harbour Investments Inc. reduced its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 16.9% during the 4th ...

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Finance, is $83.60; the latter earns a price target of $50.80 ... attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

If an investor was to purchase shares of CRSP stock at the current price level of $43.00/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock ...

But for what it's worth, Wall Street likes what it sees on the R&D side, with Citigroup ranking CRSP stock a "buy" and a consensus price target that is roughly 50% higher than current levels.

Let’s delve into the company’s strengths and weaknesses to gain a better understanding of how to play the stock amid this price rise. CRSP/VRTX’s Strong Global Launch Efforts for Casgevy The ...